Spero Therapeutics, Inc. (NASDAQ:SPRO) saw its stock surge by 240% on May 28 following the company’s announcement of the ...

GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral ...

GSK plans to submit to the US Food and Drug Administration (FDA) for regulatory approval of tebipenem HBr by the end of 2025.

Antibiotics are overused by some and out of reach for others - fuelling resistance and leaving deadly gaps in care.

In a second piece of good news in the development of new antimicrobials this week, GSK has said it will file its oral ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) saw its stock soar by 240% after announcing highly encouraging results from its Phase ...

Spero Therapeutics and partner GSK are stopping a late-stage trial of an experimental oral drug for complicated urinary tract ...

Resistance to carbapenems in Pseudomonas aeruginosa, Acinetobacter baumannii and Enterobacteriaceae, mainly determined by the production of carbapenem-hydrolyzing β-lactamases, has emerged ...

Drug makers Spero Therapeutics and GSK announced yesterday that a phase 3 trial evaluating their investigational oral ...

Event titled “BV100 Shows Survival Benefit in Phase 2 Ventilator Associated Pneumonia (VABP) Study Against Carbapenem Resistant Acinetobacter. What Does that Mean for Patients? A Perspective ...

A new study by the non-profit Global Antibiotic Research and Development Partnership (GARDP) looked at access to antibiotics for nearly 1.5 million cases of carbapenem-resistant Gram-negative ...